




REPRIEVE Insights

Quarterly Updates on Milestones and Discoveries



January 2024 Table of Contents

- [A Message from the REPRIEVE Team](#)
- [Help Us Spread the Word!](#)
- [Insights From the Field](#)
- [Two New Manuscripts Hot off the Press!](#)
- [REPRIEVE @ CROI 2024](#)
- [We Need Your Help to Share Impacts of REPRIEVE!](#)
- [REPRIEVE is #1 in TheBodyPro's Top 10 HIV Clinical Developments of 2023!](#)
- [REPRIEVE Results Sharing](#)

A Message from the REPRIEVE Team



As we send out the first REPRIEVE Insights Newsletter and celebrate this new beginning, **REPRIEVE Leadership would like to express our deepest gratitude to every REPRIEVE participant, site team, and collaborator for your valuable**

contributions. Thanks to you, we have made discoveries that are changing the lives of people with HIV across the globe.

In 2023, REPRIEVE revealed that **pitavastatin reduces major cardiovascular disease events by 35%**. Looking ahead, we are excited to share the results of the REPRIEVE Mechanistic Substudy and additional key results from REPRIEVE. Summaries of new publications, REPRIEVE in the news, and other exciting updates will all be shared in this quarterly newsletter.

We are looking forward to staying in touch in 2024 and celebrating all that we are accomplishing together. To help us spread the word about REPRIEVE, please share this newsletter with people living with HIV in your local area or anyone who might be interested in learning about REPRIEVE.

Sincerely,
REPRIEVE Leadership



Help Us Spread the Word!

During this phase of REPRIEVE, the **Clinical Coordinating Center is focused on dedicated dissemination and education efforts to support the interpretation of REPRIEVE findings and to support the adoption and implementation of guidelines in practice.** One part of this effort is this digital quarterly newsletter, *REPRIEVE Insights: Quarterly Updates on Milestones and Discoveries*.

Anyone interested in staying up-to-date with REPRIEVE activities and future publications can sign up for this newsletter. To this end, please distribute the signup link (below) and/or [click here](#) to download and distribute a flyer with a QR code to ensure that as many people as possible can stay in touch with REPRIEVE.

[REPRIEVE Insights Newsletter Sign Up Form](#)

Please share this with anyone who anyone who might be interested in receiving information about REPRIEVE. **THANK YOU!!!**



Insights From the Field

Results from REPRIEVE have been called "a necessary first step" toward a comprehensive preventive approach to reducing the risk of cardiovascular disease among people living with HIV. Results from REPRIEVE underscore the importance of cardiovascular disease prevention measures. With this in mind we reached out to the field to see the changes that are being made in practice in response to REPRIEVE. Below we share perspectives from a former REPRIEVE participant and an experienced clinician.

Alicia Diggs, REPRIEVE CAB Member

Why did you choose to participate in REPRIEVE?

I chose to participate in REPRIEVE because there has been a history of low participation from Black cisgender women in research studies for various reasons and I wanted to ensure we were represented. Also, with there being a history of heart disease in my family, it was a good opportunity to participate in a study on heart disease prevention.

What have the results of REPRIEVE meant for you?

The results of REPRIEVE made me feel really proud that I made a decision to participate in the study not just for women who look like me but for my own health. Contributing to the advancement of science and the successful outcome of the REPRIEVE trial is so monumental. The results also added to my further education on research, appreciation for research itself, and those practicing research.



What might you want to share with someone who is hesitant to participate in a clinical trial?

What I would share with someone who is hesitant to participate in a clinical trial is first, please know that advancements in science would not be successful without people participating in trials and providing their input. When making a decision to participate in a trial, your team provides you with thorough information to answer any questions you may have. A safe space is also provided to ensure that not only will your information be kept confidential but you have a say in whether you want to continue your participation or not. As a person who has been a part of clinical trials for many years, it has given me a sense of joy to be able to give back to science. To have the opportunity to provide input which is heard and taken into account by the team, that will make a positive difference for my community and other communities makes me proud. As a black cisgender woman living openly with HIV, it is important to me to participate especially when there are not many participants who look like me in studies. Also, know that there are peers available to support you throughout your journey as a clinical trial participant.



Judith Aberg, MD, REPRIEVE Protocol Vice Chair, Site Investigator, and Chief, Division of Infectious Diseases, Mount Sinai Health System

How have the results of REPRIEVE affected your practice?

Providers are starting their patients on a statin at lower ASCVD risk scores than before. Previously 7.5% was the usual risk score when statins were prescribed, and now some providers are starting statins at 5%. Providers are also ordering imaging studies such as a coronary CTA when they are on the fence as to whether a statin is really indicated especially among persons less than 50 years old. Also, there is more emphasis on a healthy heart e.g. smoking cessation, dietary changes, blood pressure management.

How have your patients reacted to learning about the REPRIEVE results?

Reactions have been very positive. Most participants wanted to continue or start a statin depending on their randomization. Non-REPRIEVE patients have been very receptive to learning more about long term outcomes associated with HIV and why a statin may be beneficial as well as learning about side effects and potential drug interactions. There has been a lot of interest from patients that there was a benefit above what was expected by lowering LDL.

How have you addressed patients who may feel hesitant to start a statin?

Some patients remain dead set that they will not take additional medications and do not feel the data are applicable to them. We continue to educate patients as appropriate on the potential benefits of statins if indicated. Some patients have had cardiac imaging to help determine if they should start a statin.

Two New Manuscripts Hot off the Press!

JAIDS

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROME

ORIGINAL ARTICLE

CMV IgG is Associated with Physical Function but not Muscle Density in People with HIV

Abidi, Maheen Z. MD¹; Umbleja, Triin MSc²; Overton, Edgar T. MD³; Burdo, Tricia PhD⁴; Flynn, Jacqueline M. BS⁴; Lu, Michael T. MD, MPH⁵; Taron, Jana MD^{5,6}; Schnittman, Samuel R. MD^{7,8}; Fitch, Kathleen V. MSN⁸; Zanni, Markella V. MD⁸; Fichtenbaum, Carl J. MD⁹; Malvestutto, Carlos MD, MPH¹⁰; Aberg, Judith A. MD¹¹; Fulda, Evelynne S. BA⁸; Eckard, Allison Ross MD¹²; Manne-Goehler, Jennifer MD¹³; Tuan, Jessica J. MD¹⁴; Ribaldo, Heather J. PhD²; Douglas, Pamela S. MD¹⁵; Grinspoon, Steven K. MD⁸; Brown, Todd T. MD, PhD¹⁶; Erlandson, Kristine M. MD¹

Author Information 

JAIDS Journal of Acquired Immune Deficiency Syndromes ():10.1097/QAI.0000000000003377, January 02, 2024. | DOI: 10.1097/QAI.0000000000003377

RESEARCH ARTICLE | JANUARY 10, 2024

Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial

 Clinical Trials & Observations

Romit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, Abhishek Niroula, Phoebe Finneran, Rachel Bernardo, Kathleen V Fitch, Michael T Lu, Gerald S Bloomfield, Carlos Malvestutto, Judith A Aberg, Carl J Fichtenbaum, Whitney Hornsby, Heather Ribaud, Peter Libby, Benjamin L Ebert, Markella Zanni, Pamela Douglas, Steven Grinspoon, Pradeep Natarajan ✉

These manuscripts, published in **JAIDS** and **Blood Advances**, share important new findings about the long-term health effects of cytomegalovirus (CMV) and clonal hematopoiesis of indeterminate potential (CHIP) in people with HIV. Visit our [publications page](#) to read the full publications and [plain language summaries](#).

 **REPRIEVE @ CROI 2024**

If you are attending CROI 2024 in Denver, CO, USA please join us at the symposium session **Follow Your Heart: Managing Cardiovascular Disease (CVD) Risk in PWH at 4:00PM on Wednesday, March 6th!**

"Overview of the REPRIEVE Trial" by Dr. Steve Grinspoon


- 1) "Sex-Differences in Atherosclerotic CVD Risks and Mechanisms: Insights from REPRIEVE" by Dr. Markella Zanni
- 2) "What's Next: Immune-Based Therapy for CVD and Comparison with the General Population" by Dr. Priscilla Hsue
- 3) "Implications for Implementing CVD Risk Prevention Strategies for Low and Middle Income Countries" by Dr. Mpiko Ntsekhe

Audience questions and discussion moderated by Drs. Steve Grinspoon, Matthew Feinstein, and Franck Boccara

REPRIEVE will also present 6 abstracts at CROI, including 2 oral presentations and 4 poster presentations. To view a schedule of all REPRIEVE activities happening at CROI, visit our website [here!](#)

We Need Your Help to Share Impacts of REPRIEVE!

Results from REPRIEVE are making an impact across the globe, from changing guidelines to changing the care of people living with HIV. If you have a story about how results from REPRIEVE have changed your care or clinical practice we want



to hear from you! Please reach out to Katie Fitch (kfitch@mgh.harvard.edu) or Marissa Diggs (mdiggs@mgh.harvard.edu) at the REPRIEVE Clinical Coordinating Center (CCC).

TheBodyPro

REPRIEVE is #1 in TheBodyPro's Top 10 HIV Clinical Developments of 2023!

Each year, TheBodyPro reviews new research and critical events that will have the greatest impact on the care of people living with HIV. This year, REPRIEVE was featured as Number 1! Dr. David Alain Wohl reviewed REPRIEVE's results very

succinctly in "REPRIEVE Will Forever Change Our Approach to Statin Use in People Living With HIV" and shared that "**The Bottom Line: Use Statins to Prevent Cardiovascular Disease in People with HIV.**"

"[G]iven the hand-wringing regarding the heightened risk people with HIV have for cardiovascular disease and accelerated or premature aging, clinicians should not slow-walk incorporating the REPRIEVE findings into practice. At the very least, start now by having informed discussions with patients about this study, statins, and other ways to avoid heart attacks and strokes." - Dr. David Alain Wohl, MD

[Click here](#) to read the full review. To read more about REPRIEVE In the News, check out [our website](#).



REPRIEVE Results Sharing

The REPRIEVE Trial website has a central webpage on which various REPRIEVE results materials are posted. The materials include:

- Graphical abstract of trial results
- Statin guidance for PWH
- Slide templates for presentations to providers
- Slide templates for presentations to the community
- Participant FAQs, and more!

If you are interesting sharing results from REPRIEVE in your local area or want to learn more this webpage is a great place to visit! Go

to: <https://www.reprievetrial.org/learnmore/results-of-the-reprieve-trial/>.

For future reference, all newsletters are available on the [REPRIEVE Website](#)

Our sponsors and collaborators



Like, comment, share, and repost!

REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital
50 Staniford St, Suite 750
Boston, MA USA 02114

This email was sent to mdiggs@mgh.harvard.edu
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

